ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
11.15 USD -2.28% Intraday chart for ALX Oncology Holdings Inc. -10.87% -25.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
UBS Adjusts ALX Oncology Price Target to $25 From $27, Maintains Buy Rating MT
H.C. Wainwright Adjusts Price Target on ALX Oncology to $20 From $17.50, Keeps Buy Rating MT
North American Morning Briefing : Stock Futures -2- DJ
Piper Sandler Adjusts Price Target on ALX Oncology Holdings to $21 From $11, Maintains Overweight Rating MT
Stifel Downgrades ALX Oncology Holdings to Hold From Buy, Adjusts Price Target to $14 From $10 MT
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : ALX Oncology Holdings Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 through Jan-11-2024
ALX Oncology Holdings Inc. and ALX Oncology Inc. Enter into the Third Amendment to Loan and Security Agreement CI
North American Morning Briefing : Investors Await -2- DJ
Top Midday Gainers MT
Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $18 From $8 MT
Stifel Trims ALX Oncology Holdings' Price Target to $10 From $11, Maintains Buy Rating MT
Sector Update: Health Care Stocks Advance Premarket Tuesday MT
ALX Oncology Reports Q3 Results With 'Sufficient' Funds to Finance Operations Into Early 2026 MT
ALX Oncology Q3 Net Loss Widens; Shares Ease After Hours MT
ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : ALX Oncology Holdings Inc. Presents at UBS Biopharma Conference 2023, Nov-08-2023 01:30 PM
Piper Sandler Raises Price Target on ALX Oncology to $11 From $8, Maintains Overweight Rating MT
ALX Oncology Closes $63.2 Million Common Stock, Warrants Offering to Fund Clinical Development of Evorpacept MT
ALX Oncology Prices Underwritten Offering of Common Stock, Warrants for Expected Gross Proceeds of $55 Million MT
ALX Oncology Commences Common Stock, Warrants Offering to Fund Development of Evorpacept MT
UBS Adjusts ALX Oncology Price Target to $27 From $29, Maintains Buy Rating MT
Cantor Fitzgerald Raises Price Target on ALX Oncology to $23 From $18, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Slipping Late Afternoon MT
Chart ALX Oncology Holdings Inc.
More charts
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
11.15 USD
Average target price
20.17 USD
Spread / Average Target
+80.87%
Consensus
  1. Stock
  2. Equities
  3. Stock ALX Oncology Holdings Inc. - Nasdaq
  4. News ALX Oncology Holdings Inc.
  5. ALX Oncology : to Collaborate With Lilly on Combination Therapy for Gastric Cancer, Gastroesophageal Junction Cancer